All AbMole products are for research use only, cannot be used for human consumption.
PTC-028 is an orally bioavailable inhibitor of stem cell factor BMI-1, it downregulates BMI-1, inducing caspase-mediated apoptosis. PTC-028 is an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification.
In vitro: PTC-028 is an orally bioavailable compound that decreases BMI-1 levels by posttranslational modification. PTC-028 treatment selectively inhibits cancer cells in clonal growth and viability assays, whereas normal cells remain unaffected. Hyperphosphorylation-mediated depletion of cellular BMI-1 by PTC-028 coupled with a concurrent temporal decrease in ATP and a compromised mitochondrial redox balance potentiates caspase-dependent apoptosis.
In vivo: In vivo, orally administered PTC-028, as a single agent, exhibits significant antitumor activity comparable with the standard cisplatin/paclitaxel therapy in an orthotopic mouse model of ovarian cancer. After administration of single oral doses to the CD-1 mice, total plasma AUC0-24h are 10.9 and 26.1 mg/h/mL at doses of 10 and 20 mg/kg, showing dose proportional pharmacokinetics. The Cmax for PTC-028 at 10 and 20 mg/kg is 0.79 and 1.49 mg/mL, respectively. The Cmax is reached at both dose levels 1-hour postdose after which plasma concentrations slowly reduce.
| Cell Experiment | |
|---|---|
| Cell lines | Immortalized ovarian surface epithelium (OSE) or the fallopian tube epithelium(FTE) cells and ovarian cancer cells |
| Preparation method | Cells are treated with PTC-028 at the indicated concentrations for 48 hours and cellular viability is assessed using the MTS assay. |
| Concentrations | 0-500 nmol/L |
| Incubation time | 48 h |
| Animal Experiment | |
|---|---|
| Animal models | Preclinical model of ovarian cancer (NCr-nu mcie; 6 to 8 weeks old) |
| Formulation | 0.5% HPMC,1% Tween 80 |
| Dosages | 10 mg/kg and 20 mg/kg |
| Administration | oral administration |
| Molecular Weight | 405.32 |
| Formula | C19H12F5N5 |
| CAS Number | 1782970-28-8 |
| Form | Solid |
| Solubility (25°C) | DMSO 90 mg/mL |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Apoptosis Products |
|---|
| 23-Hydroxybetulinic acid
23-Hydroxybetulinic acid is a novel anticancer substance. |
| TH-302 (Evofosfamide)
TH-302 is a highly potent and selective hypoxia-activated procompound targeting hypoxic regions of solid tumors with IC50 of 19 nM. |
| Se-Methylselenocysteine
Se-methylselenocysteine, a precursor of methyl selenium, has strong cancer chemoprophylaxis and antioxidant activity. Se-Methylselenocysteine has oral biological activity, can induce apoptosis. |
| Aloperine
Aloperine is exhibits anti-inflammatory, antibacterial, antiviral, and anti-tumor properties. |
| Ezatiostat
Ezatiostat (TER199, TLK199) is a glutathione analog inhibitor of glutathione S-transferase (GST) P1-1. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
